Avoiding high-fat foods, which delay stomach emptying further, is one of the most effective strategies
Particularly, individuals on medications that lower blood sugar could face a heightened risk of hypoglycemia
The safety profile of retatrutide in individuals with T2DM was also favorable [103]
It also showed particular benefits for visceral fat reduction and liver fat clearance
Trial exclusion patterns Phase 2 and Phase 3 retatrutide trials commonly excluded participants with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), severe gastroparesis, recent major cardiovascular events, severe kidney impairment, type 1 diabetes (in the obesity studies), and pregnancy or breastfeeding
For these individuals, a modified approach may be appropriate